Disclosures & Course Information
Incorporating Current NASPGHAN, ESPGHAN, and AAP Clinical Practice Guidelines
Target Audience: Registered Nurses, Pediatric Nurses, GI/Endoscopy Nurses, Family Practice Nurses
Release Date: May 2026 | Expiration Date: May 2029
Nevada State Board of Nursing Approved CE Provider (NV-14175)
The author and planning committee members have no relevant financial relationships with ineligible companies to disclose. All content has been reviewed for bias and clinical accuracy.
This continuing education activity has received no commercial support.
This educational activity includes discussion of the following off-label or investigational uses:
PEG 3350 (MiraLAX) with electrolyte solutions for pediatric bowel preparation — widely used off-label; not FDA-approved for this indication in children
Swallowed topical corticosteroids (fluticasone, budesonide) for eosinophilic esophagitis — used off-label in a swallowed (not inhaled) formulation
Evidence-Based Guidelines Referenced
NASPGHAN/ESPGHAN Joint Guidelines on Pediatric Gastroesophageal Reflux (JPGN, 2018)